	US 11,866,506 B2
	Anti-CD59 antibodies
Michael Chorev, Chestnut Hill, MA (US); and Jose A. Halperin, Brookline, MA (US)
Assigned to Mellitus, LLC, Boston, MA (US)
Appl. No. 16/606,887
Filed by Mellitus, LLC, Boston, MA (US)
PCT Filed Apr. 17, 2018, PCT No. PCT/US2018/027856 § 371(c)(1), (2) Date Oct. 21, 2019, PCT Pub. No. WO2018/195008, PCT Pub. Date Oct. 25, 2018.
Claims priority of provisional application 62/488,346, filed on Apr. 21, 2017.
Prior Publication US 2021/0284751 A1, Sep. 16, 2021
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/2896 (2013.01) [G01N 33/6893 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); G01N 2800/042 (2013.01)]

16 Claims

1. An antibody comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein:

the VH comprises:

i. a CDR-H1 having an amino acid sequence of SEQ ID NO: 39;

ii. a CDR-H2 having an amino acid sequence of SEQ ID NO: 41; and

iii. a CDR-H3 having an amino acid sequence of SEQ ID NO: 43; and

the VL comprises:

i. a CDR-L1 having an amino acid sequence of SEQ ID NO: 34;

ii. a CDR-L2 having an amino acid sequence of SEQ ID NO: 35; and

iii. a CDR-L3 having an amino acid sequence of SEQ ID NO: 37.